Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 11,000 Shares of Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at $1,053,888.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Gary Charles Robb also recently made the following trade(s):

• On Monday, August 26th, Gary Charles Robb sold 3,101 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.71, for a total value of $110,736.71.

Corcept Therapeutics Trading Up 1.0 %

Shares of CORT stock opened at $46.75 on Wednesday. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of 44.10 and a beta of 0.45. The stock has a 50-day moving average of $36.63 and a 200-day moving average of $30.93. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $47.71.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, July 29th. The biotechnology company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business had revenue of $163.80 million during the quarter, compared to analysts’ expectations of $155.14 million. During the same quarter last year, the firm posted $0.25 earnings per share. The firm’s revenue was up 39.1% on a year-over-year basis. Sell-side analysts forecast that Corcept Therapeutics Incorporated will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 579 shares in the last quarter. Park Place Capital Corp bought a new stake in Corcept Therapeutics during the second quarter worth $32,000. Atwood & Palmer Inc. bought a new stake in Corcept Therapeutics during the second quarter worth $35,000. FinTrust Capital Advisors LLC lifted its holdings in Corcept Therapeutics by 318.7% during the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,348 shares during the period. Finally, Blue Trust Inc. increased its position in Corcept Therapeutics by 125.4% in the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock worth $115,000 after buying an additional 1,962 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Piper Sandler upped their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. HC Wainwright upped their price objective on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Truist Financial upped their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $56.50.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.